Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Dempsey was not aware, that BPL was producing a product at this time (8Y) which did not transmit hepatitis; had he known about it, he would have phoned BPL and requested a supply.

  • Read more about Dr Dempsey was not aware, that BPL was producing a product at this time (8Y) which did not transmit hepatitis; had he known about it, he would have phoned BPL and requested a supply.

Dr Dempsey's patients who would have been treated with commercial concentrates and SNBTS concentrates - were infected with Hepatitis C.

  • Read more about Dr Dempsey's patients who would have been treated with commercial concentrates and SNBTS concentrates - were infected with Hepatitis C.

Children at the RBHSC with moderate haemophilia were treated with these commercial concentrates; children with mild haemophilia were treated with DDAVP and tranexamic acid.

  • Read more about Children at the RBHSC with moderate haemophilia were treated with these commercial concentrates; children with mild haemophilia were treated with DDAVP and tranexamic acid.

Dr Dempsey recalled that the pharmaceutical firms, mostly Armour, were "keen to emphasise the fact that they'd tightened up on the type of donor they looked to for their plasma source" and reassured him that he was "disposed to look favourably on commercial concentrates at that point in time."

  • Read more about Dr Dempsey recalled that the pharmaceutical firms, mostly Armour, were "keen to emphasise the fact that they'd tightened up on the type of donor they looked to for their plasma source" and reassured him that he was "disposed to look favourably on commercial concentrates at that point in time."

Dr Dempsey had gathered from reading UKHCDO minutes that things had improved considerably in relation to the safety of commercial concentrates.

  • Read more about Dr Dempsey had gathered from reading UKHCDO minutes that things had improved considerably in relation to the safety of commercial concentrates.

Dr Dempsey described batch dedication as "extremely difficult" and as something that ultimately did not work.

  • Read more about Dr Dempsey described batch dedication as "extremely difficult" and as something that ultimately did not work.

Dr Dempsey understood there was still a risk of non-A non-B Hepatitis from commercial concentrates, but there was also a risk from NHS concentrates. He acknowledged that the risk with cryoprecipitate was "very much reduced risk."

  • Read more about Dr Dempsey understood there was still a risk of non-A non-B Hepatitis from commercial concentrates, but there was also a risk from NHS concentrates. He acknowledged that the risk with cryoprecipitate was "very much reduced risk."

Dr Dempsey recalled that non-A non-B Hepatitis was not thought sufficiently serious to merit withdrawal of "the only really effective treatment for severe/moderate haemophilia" in reference to factor concentrate.

  • Read more about Dr Dempsey recalled that non-A non-B Hepatitis was not thought sufficiently serious to merit withdrawal of "the only really effective treatment for severe/moderate haemophilia" in reference to factor concentrate.

According to Dr Dempsey, in regards non-A non-B Hepatitis, around 1980 there was a "general feeling" amongst clinicians that it was not a major concern, but there were patients who did have evidence of chronic liver disease.

  • Read more about According to Dr Dempsey, in regards non-A non-B Hepatitis, around 1980 there was a "general feeling" amongst clinicians that it was not a major concern, but there were patients who did have evidence of chronic liver disease.

In Belfast, children with bleeding disorders were treated at the Royal Belfast Hospital for Sick Children until around the age of 14. They were then transferred to the haemophilia centre at the Royal Victoria Hospital.

  • Read more about In Belfast, children with bleeding disorders were treated at the Royal Belfast Hospital for Sick Children until around the age of 14. They were then transferred to the haemophilia centre at the Royal Victoria Hospital.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 41
  • Page 42
  • Page 43
  • Page 44
  • Current page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.